FUJIFILM CELLULAR DYNAMICS INC.

Company Overview

Based in Madison, Wis., FCDI develops and manufactures functioning human cells used in stem cell banking, drug discovery, toxicity testing, and cell therapy development. The company harnesses its unique manufacturing technology to produce industrial-quality differentiated tissue cells in quantity. FCDI’s technology offers the potential to create iPSCs from anyone, starting with a standard blood draw, followed by the great capability to develop into virtually any cell type of the human body.

The company’s list of some iPSC-derived cell types includes cardiomyocytes, cardiac progenitor cells, neurons, astrocytes, DopaNeurons, hepatocytes, hepatoblasts, microglia, retinal pigment epithelial cells, hematopoietic progenitor cells, mesenchymal stem cells, macrophages, and others. The company’s proprietary iCell Operating System includes true human cells in multiple cell types, human iPSCs and custom iPSCs, and derived cellular products (MyCell products).

The company’s iPSCs and derived cellular products are used for drug discovery and screening, for testing the safety and efficacy of small-molecule and biologic drug candidates, for stem cell banking, and for researching cellular therapeutics. FCDI has become the world’s largest producer of tissue cells derived from human iPSC lines, as well as a leading developer of iPSC technologies for in vitro drug development, in vivo cellular therapeutics, and stem cell banking. The company also provides iPSC reprogramming and differentiation services.

In January 2023, global developer and manufacturer of human induced pluripotent stem cells (iPSCs) FUJIFILM Cellular Dynamics Inc. announced that it had reached a nonexclusive agreement to give Novo Nordisk A/S, a global healthcare company, the right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies, with an emphasis on treating serious chronic diseases. For scientists conducting neuroscience research and drug discovery for neuroactive drugs, FUJIFILM Cellular Dynamics announced the global commercial launch of its human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit in June 2023.

FUJIFILM Cellular Dynamics Inc. launched iCell DopaNeurons for Parkinson’s disease in May 2022. The product line utilizes iPSCs derived from participants in the Michael J. Fox Foundation’s landmark study for Parkinson’s research.

Company's Business Segments

• Developing and Manufacturing of Human Cells : FUJIFILM Cellular Dynamics is a Developer, Manufacturer of Human Cells used in Drug Discovery, Toxicity Testing, Stem Cell Banking, Cell Therapy Development.